UK markets close in 6 hours 52 minutes
  • FTSE 100

    +24.44 (+0.33%)
  • FTSE 250

    +110.18 (+0.47%)
  • AIM

    +4.43 (+0.37%)

    -0.0019 (-0.16%)

    +0.0001 (+0.01%)

    -1,097.46 (-2.81%)
  • CMC Crypto 200

    -12.44 (-0.94%)
  • S&P 500

    +95.08 (+2.07%)
  • DOW

    +492.40 (+1.40%)

    -0.29 (-0.40%)

    +4.60 (+0.26%)
  • NIKKEI 225

    +405.02 (+1.42%)

    +13.21 (+0.06%)
  • DAX

    -33.16 (-0.21%)
  • CAC 40

    +10.06 (+0.14%)

Emotional Intelligence Ventures Reg A Raise at $20M, Company Pursues Psylocibin Transdermal Delivery Research, Plans Nutraceutical Mushroom Supplements Launch

·4-min read

MIAMI, October 19, 2021--(BUSINESS WIRE)--Emotional Intelligence Ventures, led by noted investor and exec David Nikzad, are pleased to announce their Regulation A raise is currently at $20,114,949, with more investors coming in daily. Ultimately, they are looking to raise a maximum of $49,999,999, and believe this is a completely doable goal. A Regulation A offering allows for retail investors to invest in pre-public and private companies. The net proceeds of the offering will be used to accelerate the development and distribution of Ei’s medicinal and functional mushroom product lines.

David Nikzad, founder and CEO of Ei.Ventures notes, "We are so committed to the nonaccredited investor, that we are pursuing a Regulation A offering." Adding, "As I’ve been fortunate to invest early in numerous companies like Airbnb, Betterment, and Vidyard, and three equity crowdfunding platforms (WeFunder, RealCrowd, Republic), I’m really passionate about democratizing investment opportunities so any investor can reap the rewards, and take all of the risks of early investment in game-changing companies."

As part of their research and development into natural psychedelic compounds, EI recently announced via Forbes that they have partnered with transdermal delivery powerhouse Tioga Research to develop a transdermal patch for sustained delivery of psilocin, the active ingredient in psilocybin mushrooms, for mental health applications.

The company believes this announcement along with the increasing interest in the psychedelic medicine for mental health space, and a rising tide of medicalization, decriminalization, and legalization of psychedelic mushrooms are driving interest in the overall psychedelic medicine space, and Ei.Ventures in particular.

On Monday October 4, the Seattle City Council voted to decriminalize the non-commercial possession and cultivation of many psychedelics, including mushrooms, for "religious, spiritual, healing, or personal growth practices." Council members passed the resolution unanimously, with a 9-0 vote. This makes Seattle the largest city in the United States to decriminalize psychedelic plants and fungi.

As part of Ei’s dual track approach, they are planning to launch their line of functional mushroom MANA nutraceuticals in early 2022. They are creating proprietary formulations using a unique formulation process for enhanced bioavailability and efficacy. These products target cognition and immune system; energy, vitality, mood, sleep, and weight loss; mental and physical optimization for micro dosers; nootropic or Smart Drugs; and joint & muscle pain.

You can find Offering Circular for Ei.Ventures’ Regulation A offering here For more information on Ei.Ventures, please go to For media needs, please contact Susan von Seggern at or 213-840-0077.

Forward Looking Statements: Certain information set forth in this presentation, together with any supplements and any other information that may be furnished to prospective investors by the Company in connection therewith, contains "forward-looking statements" and "forward-looking information" within the meaning of applicable United States securities legislation (referred to herein as forward-looking statements). Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which include but are not limited to statements related to activities, events or developments that Ei.Ventures expects or anticipates will or may occur in the future, statements related to the Company’s business strategy objectives and goals, and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as "may", "will", "could", "would", "anticipate", ‘believe", expect", "intend", "potential", "estimate", "budget", "scheduled", "plans", "planned", "forecasts", "goals" and similar expressions or the negatives thereof. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements.

View source version on


Susan von Seggern

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting